#METABOLOMICS WORKBENCH michaelsa93_20170829_140850_mwtab.txt DATATRACK_ID:1229 STUDY_ID:ST000872 ANALYSIS_ID:AN001405 PROJECT_ID:PR000604
VERSION             	1
CREATED_ON             	September 6, 2017, 8:52 am
#PROJECT
PR:PROJECT_TITLE                 	Maternal Hypoxemia and oxidative stress in the fetus, newborn, and adult.
PR:PROJECT_SUMMARY               	Gestational hypoxia presents a significant stress to an unborn fetus that can
PR:PROJECT_SUMMARY               	lead to significant complications related to fetal growth restriction and
PR:PROJECT_SUMMARY               	resulting in diseases in the newborn as well as those manifesting later in life.
PR:PROJECT_SUMMARY               	Recent evidence indicates that inflammation and oxidative stress are
PR:PROJECT_SUMMARY               	contributing factors to hypoxia-related diseases. The Center for Perinatal
PR:PROJECT_SUMMARY               	Biology at Loma Linda University has studied gestational chronic hypoxia in a
PR:PROJECT_SUMMARY               	sheep model for over 20 years to study dysfunction of vascular and nonvascular
PR:PROJECT_SUMMARY               	tissues derived from mothers, fetuses and offspring. In this project we are
PR:PROJECT_SUMMARY               	attempting to use metabolomics to assess metabolic dysregulation in vascular
PR:PROJECT_SUMMARY               	tissues along with markers of oxidative stress and inflammation in the mother
PR:PROJECT_SUMMARY               	and offspring to determine the extent of dysregulation due to chronic hypoxia.
PR:PROJECT_SUMMARY               	Untargeted metabolomics analysis focused on sheep plasma and arteries from the
PR:PROJECT_SUMMARY               	lung, resistance arteries in the brain, uterine arteries, and cultured human
PR:PROJECT_SUMMARY               	myocytes will be used to explore markers of glucose and lipid metabolism
PR:PROJECT_SUMMARY               	disruption. Targeted analyses of oxylipins and endocannabinoids will be used on
PR:PROJECT_SUMMARY               	the same samples to explore markers of oxidative stress and inflammation, which
PR:PROJECT_SUMMARY               	should be increased during hypoxia. This study should delineate pathways and
PR:PROJECT_SUMMARY               	biomarkers that help explain how hypoxia leads to the development of neonatal as
PR:PROJECT_SUMMARY               	well as adult-onset diseases associated with chronic hypoxia that are
PR:PROJECT_SUMMARY               	inter-related with fetal growth restriction.
PR:INSTITUTE                     	University of California, Davis
PR:DEPARTMENT                    	Genome and Biomedical Sciences Facility
PR:LABORATORY                    	WCMC Metabolomics Core
PR:LAST_NAME                     	Fiehn
PR:FIRST_NAME                    	Oliver
PR:ADDRESS                       	1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis,
PR:ADDRESS                       	CA 95616
PR:EMAIL                         	ofiehn@ucdavis.edu
PR:PHONE                         	(530) 754-8258
PR:FUNDING_SOURCE                	NIH U24DK097154
#STUDY
ST:STUDY_TITLE                   	Maternal Hypoxemia and oxidative stress in the fetus, newborn, and adult.
ST:STUDY_TITLE                   	exercise training for peripheral artery disease
ST:STUDY_TYPE                    	Disease model
ST:STUDY_SUMMARY                 	Gestational hypoxia presents a significant stress to an unborn fetus that can
ST:STUDY_SUMMARY                 	lead to significant complications related to fetal growth restriction and
ST:STUDY_SUMMARY                 	resulting in diseases in the newborn as well as those manifesting later in life.
ST:STUDY_SUMMARY                 	Recent evidence indicates that inflammation and oxidative stress are
ST:STUDY_SUMMARY                 	contributing factors to hypoxia-related diseases. The Center for Perinatal
ST:STUDY_SUMMARY                 	Biology at Loma Linda University has studied gestational chronic hypoxia in a
ST:STUDY_SUMMARY                 	sheep model for over 20 years to study dysfunction of vascular and nonvascular
ST:STUDY_SUMMARY                 	tissues derived from mothers, fetuses and offspring. In this project we are
ST:STUDY_SUMMARY                 	attempting to use metabolomics to assess metabolic dysregulation in vascular
ST:STUDY_SUMMARY                 	tissues along with markers of oxidative stress and inflammation in the mother
ST:STUDY_SUMMARY                 	and offspring to determine the extent of dysregulation due to chronic hypoxia.
ST:STUDY_SUMMARY                 	Untargeted metabolomics analysis focused on sheep plasma and arteries from the
ST:STUDY_SUMMARY                 	lung, resistance arteries in the brain, uterine arteries, and cultured human
ST:STUDY_SUMMARY                 	myocytes will be used to explore markers of glucose and lipid metabolism
ST:STUDY_SUMMARY                 	disruption. Targeted analyses of oxylipins and endocannabinoids will be used on
ST:STUDY_SUMMARY                 	the same samples to explore markers of oxidative stress and inflammation, which
ST:STUDY_SUMMARY                 	should be increased during hypoxia. This study should delineate pathways and
ST:STUDY_SUMMARY                 	biomarkers that help explain how hypoxia leads to the development of neonatal as
ST:STUDY_SUMMARY                 	well as adult-onset diseases associated with chronic hypoxia that are
ST:STUDY_SUMMARY                 	inter-related with fetal growth restriction.
ST:INSTITUTE                     	USDA
ST:DEPARTMENT                    	Obesity and metabolism research unit
ST:LABORATORY                    	Newman's Lab
ST:LAST_NAME                     	Newman
ST:FIRST_NAME                    	John
ST:ADDRESS                       	430 West Health Sciences Dr. Davis, Ca, 95616
ST:EMAIL                         	John.Newman@ars.usda.gov
ST:PHONE                         	(530) 752-1009
#SUBJECT
SU:SUBJECT_TYPE                  	Sheep
SU:SUBJECT_SPECIES               	Ovis aries
SU:TAXONOMY_ID                   	9940
SU:GENDER                        	Both
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	A10	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B04	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	C10	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B05	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B02	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	E03	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	G09	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	E05	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	C05	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	D05	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B07	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	C03	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	H04	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	F01	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	F04	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B01	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	G08	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	E04	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	E01	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	F05	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	C07	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	E10	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	H02	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	A07	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	A04	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	D09	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	H08	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	F08	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	A09	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	G04	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	A01	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	E08	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	C02	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	E09	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	C06	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	G07	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	(D06 + H01) / 2	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	(A02 + H09) / 2	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	G03	Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B08	Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	H06	Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	H07	Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B09	Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	A06	Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	B03	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	E02	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	G05	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	G01	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	D02	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	A03	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	A05	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	G02	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	F10	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	
SUBJECT_SAMPLE_FACTORS           	-	F02	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	E06	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	H05	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	D01	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	D08	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	D07	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	C08	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	C09	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	E07	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	D04	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	C04	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	F07	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
SUBJECT_SAMPLE_FACTORS           	-	(D03 + F09) / 2	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	
#COLLECTION
CO:COLLECTION_SUMMARY            	Whole blood was immediately separated by centrifugation and the plasma frozen in
CO:COLLECTION_SUMMARY            	liquid nitrogen and stored at -80C for later analysis.
CO:SAMPLE_TYPE                   	Blood
CO:BLOOD_SERUM_OR_PLASMA         	Venous and arterial plasma
#TREATMENT
TR:TREATMENT_SUMMARY             	To induce chronic hypoxia, pregnant and non-pregnant ewes were transported to
TR:TREATMENT_SUMMARY             	the White Mountain Research Station that is owned and operated by the University
TR:TREATMENT_SUMMARY             	of California. Animals were housed at the Barcroft Research Station (3800 m) for
TR:TREATMENT_SUMMARY             	100+ days prior to having the pregnant or non-pregnant ewes or 2 week old
TR:TREATMENT_SUMMARY             	newborn lambs transported back to Loma Linda for study.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	After randomization, a 50 μl plasma aliquot in a 1.5 mL polypropylene Eppendorf
SP:SAMPLEPREP_SUMMARY            	tube was enriched with deuterated surrogates in 10 µL methanol (Tables S1 and
SP:SAMPLEPREP_SUMMARY            	S2 from Agrawal, K., L.A. Hassoun, N. Foolad, T.L. Pedersen, R.K. Sivamani, J.W.
SP:SAMPLEPREP_SUMMARY            	Newman. 2017. Sweat lipid mediator profiling: a non-invasive approach for
SP:SAMPLEPREP_SUMMARY            	cutaneous research. J. Lipid Res. 58:188–195 [EPub: Nov 7, 2016]. doi:
SP:SAMPLEPREP_SUMMARY            	10.1194/jlr.M071738) and 5 μl of BHT/EDTA in 1:1 methanol/water (v/v). A total
SP:SAMPLEPREP_SUMMARY            	of 200 μl 1-cyclohexyl uredio, 3-dodecanoic acid / 1-phenyl ureido, 3-hexanoic
SP:SAMPLEPREP_SUMMARY            	acid (CUDA / PUHA) in 1:1 methanol/acetonitrile (v/v) was added, the sample
SP:SAMPLEPREP_SUMMARY            	mixed by vortexing and protein precipitate was removed by centrifugation (10
SP:SAMPLEPREP_SUMMARY            	min, 10,000 RCF, 6 °C). The supernatant was filtered by centrifugation through
SP:SAMPLEPREP_SUMMARY            	1 µm PVDF membranes (Millipore, Billerica, MA) at 6 °C and 4,500 RCF for 3
SP:SAMPLEPREP_SUMMARY            	min. The filtrate was stored in glass vials at -20 °C until UPLC-MS/MS
SP:SAMPLEPREP_SUMMARY            	analysis.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Aquity C18 BEH 1.7µm 100mm x 2.1mm column
CH:FLOW_GRADIENT                 	See protocol/methods file
CH:FLOW_RATE                     	0.25 mL/min
CH:COLUMN_TEMPERATURE            	60 °C
CH:SOLVENT_A                     	0.1% acetic acid
CH:SOLVENT_B                     	90% ACN / 10% IPA
CH:INTERNAL_STANDARD             	See protocol/methods file
CH:RETENTION_TIME                	See protocol/methods file
CH:SAMPLE_INJECTION              	5 µL
CH:ANALYTICAL_TIME               	20 min
CH:WEAK_WASH_SOLVENT_NAME        	20% methanol, 10% isopropanol
CH:WEAK_WASH_VOLUME              	600 µL
CH:STRONG_WASH_SOLVENT_NAME      	50:50 Acetonitrile:Methanol
CH:STRONG_WASH_VOLUME            	600 µL
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	ABI Sciex 6500 QTrap
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	Concentration (nM)
MS_METABOLITE_DATA_START
Samples	A09	D09	H08	A01	C02	C06	E08	E09	G04	G07	F08	B07	C03	C05	C07	D05	(D06 + H01) / 2	E04	G08	E01	E10	F05	H02	H04	B01	F01	F04	A04	A07	A10	B02	B04	B05	E03	E05	G09	(A02 + H09) / 2	C10	C04	C08	C09	(D03 + F09) / 2	D04	D07	D08	E07	F07	A03	A05	D02	F10	G02	D01	E06	F02	H05	B03	E02	G01	G05	A06	B09	H07	B08	G03	H06
Factors	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous	Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous	Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous
PEA	99.2	76.7	94.9	136	69.1	78.9	48.7	110	60.2	51	62.9	67.8	75.9	60.7	52.3	74.1	79.35	42.3	66.9	68.8	89	58.3	75.9	54.7	119	85.9	78.3	112	86.7	88.5	69.9	81.4	81.1	46	46.2	65.3	94.85	64.8	98.6	57.9	72.9	78.75	96.4	80	69.4	56.8	69	143	107	87.5	75.7	131	72.7	63.9	51.3	98.8	90.4	62	68.2	62.7	106	42.7	88.6	64.6	82.5	59.9
SEA	117	89.5	108	274	106	90.1	82.3	147	58.3	91	97.4	151	138	101	87.4	108	117.5	92.9	67.3	95.3	126	87.5	144	106	247	129	85.1	191	158	164	127	164	164	134	75	92.3	159.5	66.9	89.8	61.3	94	94	126	103	51.7	72.5	83.2	168	132	103	84.9	176	103	73.8	57.1	119	161	86.1	79.1	64.6	223	82.6	134	128	144	102
OEA	2.77	2.4	2.44	2.82	1.55	1.56	1.27	1.09	1.99	0.997	1.86	4.99	1.6	2.73	1.72	2.19	2.795	1.59	1.98	1.25	1.12	1.79	2.51	2.12	4.66	1.61	1.54	2.37	1.28	2.18	1.85	2.03	2.86	11	1.13	1.77	3.06	3.85	1.17	0.825	0.972	0.91	1.04	1.43	0.735	0.918	0.963	0.888	1.17	0.696	1.2	1.75	1.8	2.03	1.95	2	2.38	1.66	1.9	1.39	2.34	2.26	1.99	5.19	2.75	5.34
LEA	0.307	0.315	0.368	0.343	0.273	0.364	0.203	0.168	0.339	0.214	0.449	0.448	0.288	0.481	0.243	0.387	0.869	0.252	0.39	0.239	0.261	0.326	0.448	0.289	0.588	0.384	0.352	0.27	0.0958	0.31	0.189	0.238	0.271	0.701	0.228	0.308	0.473	0.546	0.0686	0.0396	0.0394	0.0245	0.0291	0.0651	0.0268	0.0399	0.0379	0.0418	0.0299	0.0378	0.0771	0.0876	0.0606	0.0956	0.0711	0.0444	0.0726	0.0694	0.0673	0.0609	0.466	0.528	0.437	0.552	0.506	0.877
aLEA	0.0383	0.0583	0.042	0.039	0.0569	0.0466	0.0348	0.0184	0.0378	0.0311	0.0336	0.0511	0.0278	0.056	0.0253	0.064	0.06805	0.0454	0.0513	0.0325	0.0327	0.0492	0.0718	0.0233	0.0434	0.0335	0.0355	0.104	0.0453	0.114	0.0619	0.0537	0.101	0.0925	0.0766	0.138	0.1023	0.233	0.00552	0.00153	ND	0.00839	0.00259	0.00309	0.00316	0.0061	0.00267	0.00493	0.00559	0.0035	0.00136	0.0122	0.00942	0.00943	0.0142	0.00938	0.00995	0.0143	0.0107	0.0221	0.0599	0.0852	0.0502	0.281	0.163	0.291
DGLEA	0.0212	0.022	0.0418	0.0373	0.0487	0.0355	0.00976	0.0233	0.03	0.0374	0.0637	0.0953	0.057	0.0643	0.0291	0.0551	0.07855	0.106	0.0686	0.0391	0.024	0.0517	0.0562	0.0358	0.12	0.0282	0.0343	0.0109	0.0186	0.0769	0.0451	0.0294	0.0132	0.0686	0.00895	0.0294	0.0537	0.00655	0.0064	0.00512	0.000311	0.01735	ND	0.00208	0.00704	0.0104	0.00983	0.00308	0.0123	0.0121	0.00707	0.0142	0.00753	0.0182	0.0159	0.00863	0.0312	0.0164	0.00639	0.000124	0.0373	0.0641	0.0173	0.033	0.0555	0.0249
AEA	0.109	0.164	0.0943	0.0825	0.115	0.0852	0.0386	0.0429	0.0767	0.0514	0.107	0.0799	0.064	0.135	0.0659	0.166	0.2505	0.0888	0.0992	0.0618	0.0658	0.104	0.114	0.0755	0.204	0.142	0.098	0.0763	0.0479	0.0973	0.0473	0.0412	0.082	0.185	0.0684	0.0729	0.176	0.105	0.0985	0.056	0.0403	0.0468	0.00438	0.0896	0.0555	0.0226	0.0307	0.0315	0.0297	0.0263	0.0417	0.0868	0.0583	0.053	0.0927	0.0633	0.0744	0.0615	0.0659	0.0432	0.0887	0.0814	0.0458	0.0743	0.0795	0.0945
DEA	0.255	0.329	0.366	0.417	0.37	0.403	0.2	0.151	0.549	0.372	0.43	0.247	0.387	0.59	0.294	0.223	0.746	0.351	0.277	0.217	0.216	0.489	0.166	0.446	0.73	0.418	0.485	0.171	0.149	0.287	0.228	0.0965	0.438	0.558	0.123	0.194	0.2135	0.409	0.475	0.293	0.274	0.2025	0.3	0.612	0.489	0.225	0.443	0.489	0.26	0.13	0.34	0.725	0.512	0.382	0.0744	0.382	0.2	0.382	0.274	0.0308	0.691	0.819	1.26	0.488	0.641	0.327
DHEA	0.117	0.192	0.142	0.166	0.207	0.18	0.125	0.0828	0.106	0.134	0.15	0.196	0.107	0.173	0.138	0.257	0.2335	0.248	0.169	0.228	0.226	0.293	0.257	0.0681	0.259	0.154	0.117	0.147	0.136	0.138	0.225	0.172	0.245	0.14	0.167	0.222	0.1865	0.193	0.138	0.182	0.0864	0.136	0.119	0.314	0.119	0.1	0.122	0.213	0.109	0.168	0.0879	0.199	0.263	0.245	0.31	0.239	0.214	0.333	0.196	0.179	0.233	0.229	0.195	0.465	0.733	0.538
NO-Gly	7.75	6.38	4.94	3.28	1.53	2.33	1.99	1.24	4.01	1.95	5.65	6.03	5.64	8.28	3.3	7.05	8.44	3.94	6.15	2.28	1.78	3.59	4.73	4.39	6.64	2.33	2.91	5.17	2.57	8.93	3.35	3.39	7.48	4.67	6.07	6.19	9.475	15.1	0.907	0.521	0.476	1.585	1.13	2.77	0.57	1.4	1.5	1.16	0.686	0.864	1.32	1.51	1.16	1.78	1.9	1.5	1.8	2.03	1.16	1.48	2.9	3.44	3.04	2.26	2.82	2.59
NA-Gly	0.169	0.123	0.231	0.195	0.0823	0.17	0.0868	0.0606	0.212	0.1	0.332	0.252	0.124	0.333	0.0605	0.234	0.1755	0.123	0.205	0.14	0.104	0.0506	0.135	0.11	0.215	0.0966	0.089	0.157	0.0393	0.22	0.148	0.0484	0.351	0.0207	0.134	0.233	0.2165	0.609	0.164	0.0295	0.0608	0.1155	0.009	0.13	0.105	0.144	0.123	0.153	0.0741	0.136	0.0988	0.413	0.136	0.0924	0.106	0.0876	0.105	0.115	0.063	0.086	0.114	0.231	0.181	0.0316	0.249	0.152
OG	502	181	698	956	361	636	787	1590	317	802	61.6	46.8	72.3	26.1	19.4	79.6	107.4	34.1	40.4	46.6	244	107	19.6	71	160	265	218	35.3	43.7	21.9	50.8	32.6	56.8	68.5	20.2	97.1	139	59.5	13.6	10.6	12.2	14	26.5	171	25.6	23.6	16.3	35.2	24.4	24.9	49	67.7	19.8	26.3	37.7	22.7	1.7	41.2	37.7	14	3270	4050	3180	8860	886	5380
LG	82.4	22.8	45.4	168	137	443	109	151	48	128	12.9	86.2	54.8	10.5	7.23	36.1	78.85	21.1	53.6	35.6	258	71.3	16.1	36.6	249	309	113	13.6	10.6	7.33	17.7	0.803	29.2	22.2	17.1	7.84	68.05	21.7	6.68	3.99	1.59	6.99	6.28	20.4	7.18	10.2	4.34	9.44	6.27	6.24	8.24	20.1	3.27	17.1	4.88	5.64	107	7.78	5.59	7.32	540	727	820	1340	160	727
AG	0.869	2.2	1.45	1.52	10.7	35.1	2.49	4.53	1.85	2.21	1.42	1.56	3.09	1.6	1.32	4.7	6.425	1.53	3.29	2.62	14.7	7.11	2.52	2.89	9.09	19	12.3	0.957	1.79	1.18	1.67	1.49	1.94	2.74	0.584	1.07	4.735	2.18	2.61	1.74	2.93	2.485	2.24	10.4	6.54	1.83	4.14	2.39	2.77	1.63	4.28	11.9	5.85	3.83	4.17	1.36	4.56	4.78	4.71	1.26	19.1	38.5	44.1	63.5	11.4	39.5
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	PubChem ID	KEGG ID	Parent Lipid	Class	HMDB ID	InChIKey
PEA	4671	C16512	C16:0	Ethanolamide	HMDB02100	HXYVTAGFYLMHSO-UHFFFAOYSA-N
SEA	27902		C18:0	Ethanolamide	HMDB13078	OTGQIQQTPXJQRG-UHFFFAOYSA-N
OEA	5283454		C18:1n9	Ethanolamide	HMDB02088	BOWVQLFMWHZBEF-KTKRTIGZSA-N
LEA	5283446		C18:2n6	Ethanolamide	HMDB12252	KQXDGUVSAAQARU-HZJYTTRNSA-N
aLEA	5283449		C18:3n3	Ethanolamide	HMDB13624	HBJXRRXWHSHZPU-PDBXOOCHSA-N
DGLEA	5282272	C13828	C20:3n6	Ethanolamide	HMDB13625	ULQWKETUACYZLI-QNEBEIHSSA-N
AEA	5281969	C11695	C20:4n6	Ethanolamide	HMDB04080	LGEQQWMQCRIYKG-DOFZRALJSA-N
DEA	5282273	C13829	C22:4n6	Ethanolamide	HMDB13626	FMVHVRYFQIXOAF-DOFZRALJSA-N
DHEA	53245830		C22:6n3	Ethanolamide	HMDB13627	CXWASNUDKUTFPQ-KUBAVDMBSA-N
NO-Gly	6436908		C18:1n9	N-Acyl Glycine	HMDB13631	HPFXACZRFJDURI-KTKRTIGZSA-N
NA-Gly	5283389		20:4n6	N-Acyl Glycine	HMDB05096	YLEARPUNMCCKMP-DOFZRALJSA-N
OG	Sum (12178130 + 5319879)		C18:1n9	1- and 2-Acyl Glycerol	Sum (HMDB11567 + HMDB11537)	Sum (RZRNAYUHWVFMIP-QJRAZLAKSA-N + UPWGQKDVAURUGE-KTKRTIGZSA-N)
LG	Sum (6436630 + 5365676)		C18:2n6	1- and 2-Acyl Glycerol	Sum (HMDB11568 + HMDB11538)	Sum (WECGLUPZRHILCT-GSNKCQISSA-N + IEPGNWMPIFDNSD-HZJYTTRNSA-N)
AG	Sum (16019980 + 5282280)		C20:4n6	1- and 2-Acyl Glycerol	Sum (HMDB11578 + HMDB04666)	Sum (DCPCOKIYJYGMDN-HUDVFFLJSA-N + RCRCTBLIHCHWDZ-DOFZRALJSA-N)
METABOLITES_END
#END